Trial Profile
A Pilot, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Raltegravir Versus NRTIs as a Backbone in HIV-Infected Patients Switched From a Stable Boosted PI Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; HIV protease inhibitors; Nucleoside reverse transcriptase inhibitors
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2011 Actual end date Jul 2011 added as reported by ClinicalTrials.gov.
- 01 Nov 2011 Actual end date Jul 2011 added as reported by ClinicalTrials.gov.
- 01 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.